Trial NCT03924245

View at ClinicalTrials.gov 
Org. Study IDs: VICC GYN 1842
Secondary IDs: NCI-2019-02322

Last trial update was posted on 2022-04-04

MeSH Interventions

Entinostat Olaparib

MeSH Conditions

Adenocarcinoma Adenocarcinoma, Clear Cell Carcinoma Carcinoma, Endometrioid Carcinosarcoma Cystadenocarcinoma, Serous Endometrial Neoplasms Fallopian Tube Neoplasms Mixed Tumor, Mullerian Recurrence

Other Conditions

Fallopian Tube Cancer Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma High Grade Fallopian Tube Serous Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Ovarian Carcinosarcoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Endometrial Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Stopping Reasons

Change in participant landscape and other treatment availability

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID